India's Cipla to Build Biosimilar Plant in South Africa

Mumbai-based Cipla announced plans to build a $89 million biosimilar manufacturing plant in the coastal city of Durban.

The Cipla BioTec plant -- the first South African facility for Cipla's biotechnology arm -- will manufacture biosimilars at lower costs for South Africa. There is also potential to export to the U.S., Europe and Asia, said the company.

Construction for the new facility is scheduled to start in early 2017, with full operations expected to commence in the third quarter of 2018.

Several drugmakers are joining the growing group of protestors who are distancing themselves from the Fox News Channel shows featuring Tucker Carlson and Jeanine Pirro after the hosts were accused of making bigoted statements.

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.